)
)
)
KYAN Technologies is a functional precision medicine platform company dedicated to revolutionizing cancer care through our platform Optim.AI. This powerful tool empowers oncologists by providing them with critical insights to make informed clinical decisions for their patients. Optim.AI integrates small data AI and biological experiments to offer an efficient solution that transforms the identification of optimal outcomes from vast drug-dose combinations, revolutionizing the development and delivery of therapies to patients. In addition to our clinical test, KYAN is committed to conducting extensive research studies across various cancer indications to not only contribute to the advancement of biopharma services but also aid in the development of novel biopharmaceutical assets.
Year Founded
2022
Next catalyst (value inflection) update
We have successfully launched Optim.AI in Asia. Next value inflection is the launch of our clinical test and expanding our patient customer base in the US through Mayo and other US partners.
Expected time of next catalyst update
June, 2026
City
Singapore
Country
Singapore
Company CEO or top company official
Hugo Saavedra
Development Phase of Primary Product
Multiple Products in Market
Lead Product in Development
Optim.AI
Number of Unlicensed Products
1
Therapeutic Area
Diagnostics
Website
https://kyantechnologies.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
